Jubilant Pharmova Q4 Net Profit Drops 20% to ₹120 Crore Amid Montreal Facility Costs

Market snapshot: Jubilant Pharmova has reported a divergence between its top-line and bottom-line performance for the final quarter of FY26. While consolidated revenue surged nearly 19% to ₹2,290 Crore, the consolidated net profit contracted by 20% to ₹120 Crore. The performance was largely impacted by higher depreciation and remediation costs at the Montreal CMO facility, though management signals a clear path to margin recovery by late FY27.

Data Snapshot

• Q4 Net Profit: ₹120 Crore (vs ₹150 Crore YoY)
• Q4 Revenue: ₹2,290 Crore (vs ₹1,928 Crore YoY)
• Full Year Revenue: ₹8,280 Crore (+14% YoY)
• FY26 Final Dividend: ₹5 per equity share
• Net Debt/EBITDA Ratio: 1.3x (as of Dec 2025)

What's Changed

• Profitability has shifted from ₹150 Crore to ₹120 Crore on a YoY basis, representing a 20% contraction.
• Revenue expanded by ₹361 Crore, driven by the Spokane Line 3 ramp-up and Ruby-Fill growth.
• EBITDA margins are currently under pressure due to the stabilization of Montreal production, shifting the expected recovery timeline to H2 FY27.

Key Takeaways

• Contract manufacturing (CDMO) in North America remains the primary revenue driver, contributing to the 18.7% revenue jump.
• The Montreal facility remediation, following USFDA OAI status in early 2026, has resumed production but continues to incur higher depreciation and maintenance costs.
• Radiopharmaceuticals, specifically the Ruby-Fill portfolio, saw sustainable growth, offsetting some generic market headwinds.

SAHI Perspective

From the SAHI perspective, Jubilant Pharmova is undergoing a structural transition. The sacrifice in near-term profitability to resolve regulatory hurdles at the Montreal site and invest in the Spokane expansion is a calculated move for long-term capacity building. The 1.3x Net Debt/EBITDA ratio indicates a stable balance sheet, providing the company with a buffer while it waits for the H2 FY27 margin expansion. Investors should note that while the headline profit drop looks sharp, the robust top-line growth suggests underlying demand for their specialty injectable and radiopharma services remains intact.

Market Implications

The mixed results indicate that capital allocation is heavily skewed toward facility stabilization and regulatory compliance. Market impact for JUBLPHARMA may remain neutral to slightly bearish in the short term as analysts recalibrate EPS estimates for FY27. However, the sector-wide trend toward high-margin CDMO work and radiopharmaceuticals suggests that long-term capital allocation signals are positive, provided the Montreal facility hits targeted utilization rates by mid-2026.

Trading Signals

Market Bias: Neutral

Revenue growth of 18.7% is balanced against a 20% profit decline and delayed margin recovery until H2 FY27, suggesting a period of consolidation.

Overweight: Radiopharmaceuticals, CDMO Sterile Injectables

Underweight: US Generics, API Manufacturing

Trigger Factors:

• Utilization rates at the Spokane Line 3 facility
• USFDA reinspection outcomes for Montreal and Salisbury sites
• Quarterly EBITDA margin trajectory toward the 22-24% target

Time Horizon: Near-term (0-3 months)

Industry Context

The Indian pharmaceutical sector is pivoting away from high-competition generics toward specialty services. Jubilant Pharmova's focus on Radiopharmaceuticals and CDMO Sterile Injectables aligns with global supply chain shifts. The recent 25% increase in Ruby-Fill hospital placements highlights the competitive advantage in niche diagnostic imaging, even as larger firms face pricing pressure in standard oral solids in the US market.

Key Risks to Watch

• Continued regulatory scrutiny if remediation efforts at Montreal do not satisfy USFDA during the next audit.
• Higher-than-expected depreciation from the $300 Million+ total investment in North American facilities.
• Raw material volatility in the isotope distribution chain impacting radiopharma margins.

Recent Developments

In February 2026, the USFDA classified the Montreal facility as 'Official Action Indicated' (OAI), though production resumed by Q4 FY26. Additionally, the Spokane facility successfully launched its third Sterile Fill & Finish line in late 2025, which has now started contributing to incremental CDMO revenue. The company also completed the divestment of its API business to Jubilant Biosys in late 2025 to streamline its CRDMO operations.

Closing Insight

Jubilant Pharmova is trading off immediate earnings for future-proof capacity. The stabilization of the Montreal plant remains the pivot point for the stock's re-rating in H2 FY27.

FAQs

Why did Jubilant Pharmova's net profit drop 20% despite higher revenue?

The decline was primarily caused by higher depreciation costs and operational expenses associated with the remediation and stabilization of the Montreal production facility following earlier USFDA observations.

When does the company expect EBITDA margins to recover?

Management has guided for EBITDA margins to strengthen starting from the second half of FY27 (H2 FY27), as capacity utilization at Montreal and Spokane improves.

How does the USFDA OAI status in Montreal affect future production?

While production resumed in Q4 FY26, the OAI status means the facility is under high scrutiny; successful remediation is critical to prevent further regulatory halts that could disrupt the projected revenue ramp-up.

What is the significance of the Ruby-Fill growth for retail investors?

Ruby-Fill represents a high-margin specialty diagnostic product; its 25% hospital placement growth indicates strong market penetration in the US, which provides a more stable revenue floor compared to volatile generic drugs.

High Performance Trading with SAHI.